Molecular Pharmaceutics最新文献

筛选
英文 中文
Mechanistic Insights into Drug Release from PLGA- and PLA-Based Implants PLGA和基于PLGA的植入物药物释放的机理研究
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-09-25 DOI: 10.1021/acs.molpharmaceut.6c00399
Dongyue Yu, Ryan Schroder, Arnold Teo, Sarah C. Traeger, Laura I. Mosquera-Giraldo, Marc Fancher, France Landry, Yongliang Zhang, Elena Grajales, Christopher G. Levins, Xue-Qing Chen, Janet Caceres Cortes, Kimberly A. Foster, Christoph Gesenberg
{"title":"Mechanistic Insights into Drug Release from PLGA- and PLA-Based Implants","authors":"Dongyue Yu,&nbsp;Ryan Schroder,&nbsp;Arnold Teo,&nbsp;Sarah C. Traeger,&nbsp;Laura I. Mosquera-Giraldo,&nbsp;Marc Fancher,&nbsp;France Landry,&nbsp;Yongliang Zhang,&nbsp;Elena Grajales,&nbsp;Christopher G. Levins,&nbsp;Xue-Qing Chen,&nbsp;Janet Caceres Cortes,&nbsp;Kimberly A. Foster,&nbsp;Christoph Gesenberg","doi":"10.1021/acs.molpharmaceut.6c00399","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00399","url":null,"abstract":"<p>Biodegradable polymer implants offer long-acting drug delivery, yet the roles of polymer chemistry and drug properties in governing release remain incompletely understood. We hypothesized that polymer viscosity and end-group chemistry regulate water uptake, glass-transition, and chain mobility, thereby controlling implant dissolution and drug release. To test this, drug-loaded implants were fabricated using PLGA and PLA polymers with varied inherent viscosities, lactide/glycolide ratios, and end-group chemistries via vacuum compression molding, and characterized using water-uptake studies, dissolution testing, and NMR analyses. Low-viscosity, acid-terminated polymers showed rapid water uptake and a marked reduction in glass-transition temperature, inducing a transition to a rubbery state with enhanced chain mobility. These changes accelerated implant dissolution and drug release. Drug solubility further modulated drug release: acetaminophen promoted fast dissolution, whereas dexamethasone exhibited slower, polymer-controlled release. The formulations demonstrated a clear in vitro−in vivo relationship, supporting their relevance for preclinical evaluation. Overall, the results establish how polymer chemistry, polymer mobility, and drug physicochemical properties collectively determine release performance, providing a mechanistic basis for designing biodegradable implants with tunable profiles.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5352–5366"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149306014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual Antifibrotic Modulation via CTGF Silencing and Peptide Amphiphile Nanofibers for Topical Treatment of Skin Fibrosis 通过CTGF沉默和肽两亲纳米纤维局部治疗皮肤纤维化的双重抗纤维化调节
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-09-25 DOI: 10.1021/acs.molpharmaceut.6c00479
Ayça Eroğlu, Gulcihan Gulseren, Deniz Sezlev Bilecen
{"title":"Dual Antifibrotic Modulation via CTGF Silencing and Peptide Amphiphile Nanofibers for Topical Treatment of Skin Fibrosis","authors":"Ayça Eroğlu,&nbsp;Gulcihan Gulseren,&nbsp;Deniz Sezlev Bilecen","doi":"10.1021/acs.molpharmaceut.6c00479","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00479","url":null,"abstract":"<p>Skin fibrosis is driven in part by transforming growth factor-β (TGF-β) signaling and the matricellular protein connective tissue growth factor (CTGF). Elevated CTGF expression is a hallmark of fibrotic skin lesions and contributes to pathological extracellular matrix remodeling. In this project, an antisense oligonucleotide (AON) delivery system was developed for the treatment of skin fibrosis. In this respect, two antifibrotic agents, i) AON against CTGF and ii) antifibrotic polypeptide amphiphile, were self-assembled into nanofibers to enhance antifibrotic efficacy. The nanofibers were encapsulated in chitosan nanoparticles (CNPs) for protection and sustained release. Loaded CNPs were characterized by morphology, size, endosomal escape, and skin penetration using a transwell-based 3D skin model. The nanoparticles exhibited an average size of 220 nm. The encapsulation efficiency of CNPs was 52%, providing sustained nanofiber release over 7 days. With the use of nanoparticles, clear reduction trends were observed in CTGF, α-smooth muscle actin (αSMA), and collagen expression. CNPs penetrated the skin model gradually, revealing no cytotoxicity to skin cells. Overall, these results reveal the potential of the designed nanofibers as a therapeutic agent and the CNPs as the carrier of the nanofibers. The developed delivery system can be used as an alternative approach for the treatment of lesions in fibrotic skin.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5399–5411"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149306017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Superior Therapeutic Efficacy and Reduced Systemic Toxicity of a Cucurbit[7]uril-Camptothecin Supramolecular Complex in Colorectal Cancer 葫芦-喜树碱超分子复合物在结直肠癌中的优越疗效和降低全身毒性
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-09-30 DOI: 10.1021/acs.molpharmaceut.6c00800
Chenbing Niu, Jingqiu Zhang, Yating Zhang, Yinxia Chang, Shengnan Xiao, Xuemei Qin
{"title":"Superior Therapeutic Efficacy and Reduced Systemic Toxicity of a Cucurbit[7]uril-Camptothecin Supramolecular Complex in Colorectal Cancer","authors":"Chenbing Niu,&nbsp;Jingqiu Zhang,&nbsp;Yating Zhang,&nbsp;Yinxia Chang,&nbsp;Shengnan Xiao,&nbsp;Xuemei Qin","doi":"10.1021/acs.molpharmaceut.6c00800","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00800","url":null,"abstract":"<p>The clinical application of camptothecin (CPT) is limited by poor solubility and severe toxicity. This study compares the therapeutic performance of a cucurbit[7]uril-based CPT complex (CB[7]-CPT) with free CPT and β-cyclodextrin-CPT (β-CD-CPT) in colorectal cancer models. <em>In vitro</em>, free CPT, β-CD-CPT, and CB[7]-CPT were tested on normal LO2 and cancerous HCT116 cells. CB[7] encapsulation reduced toxicity toward normal LO2 cells (IC<sub>50</sub>: 0.47 μM, ∼25-fold higher than the IC<sub>50</sub> of free CPT) while improving potency against HCT116 cells (CB[7]-CPT IC<sub>50</sub>: 0.24 μM; free CPT IC<sub>50</sub>: 0.55 μM, ∼2-fold more potent than free CPT). The selectivity index improved from 0.034 (CPT) to 1.976 (CB[7]-CPT), indicating a wide safety margin. Apoptosis assays confirmed that CB[7]-CPT induced significantly greater apoptotic cell death at equivalent concentrations than either free CPT or β-CD-CPT. In HCT116 xenograft models, CB[7]-CPT achieved a tumor inhibition rate of 76%, markedly outperforming free CPT (46%) and β-CD-CPT (62%). This enhanced efficacy was accompanied by increased intratumoral apoptosis, reduced proliferation, and decreased microvessel density. Importantly, CB[7]-CPT markedly attenuated liver, kidney, and gastrointestinal toxicity typically associated with CPT exposure. Pharmacokinetically, CB[7]-CPT displayed a 1.94-fold higher AUC and a 1.59-fold prolonged elimination half-life relative to free CPT, reflecting extended circulation and improved systemic exposure. These findings collectively establish CB[7]-CPT as a highly effective and safer alternative not only to free CPT but also to conventional cyclodextrin-based formulations, demonstrating enhanced selectivity, robust pro-apoptotic activity, and a superior safety profile.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5674–5690"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preclinical Study of the 89Zr/177Lu-Labeled Engineered VHH-based Antibody for CLDN18.2-Targeted Radiotheranostics 89Zr/ 177lu标记工程化vhh抗体用于cldn18.2靶向放射治疗的临床前研究
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-10-14 DOI: 10.1021/acs.molpharmaceut.6c01174
Wenyu Wu, Guoqiang Shao, Yilin Xue, Jun Chen, Zhaoyang Zhao, Jingjing Fu, Rui Yang, Hai Qian, Hanmei Xu
{"title":"Preclinical Study of the 89Zr/177Lu-Labeled Engineered VHH-based Antibody for CLDN18.2-Targeted Radiotheranostics","authors":"Wenyu Wu,&nbsp;Guoqiang Shao,&nbsp;Yilin Xue,&nbsp;Jun Chen,&nbsp;Zhaoyang Zhao,&nbsp;Jingjing Fu,&nbsp;Rui Yang,&nbsp;Hai Qian,&nbsp;Hanmei Xu","doi":"10.1021/acs.molpharmaceut.6c01174","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c01174","url":null,"abstract":"<p>Claudin 18.2 (CLDN18.2) is a tight junction protein aberrantly expressed in gastric and pancreatic cancer. In this study, we developed the novel nanobody 18.2−50H and VHH-Fc fusion antibody 18.2−50C radiolabeled with <sup>89</sup>Zr/<sup>177</sup>Lu for CLDN18.2-targeted radiotheranostics. Zolbetuximab (IMAB362), 18.2−50H, and 18.2−50C were conjugated with DFO and labeled with <sup>89</sup>Zr, respectively. Radiochemical purity and in vitro stability were determined by radio-TLC. CLDN18.2-targeting specificity was evaluated using HEK-293T and HEK-293T/CLDN18.2 cells. PET/CT imaging and biodistribution studies were performed in mouse models and cynomolgus monkeys. Subsequently, <sup>177</sup>Lu-DOTA-18.2-50C was prepared and assessed for tumor targeting in gastric cancer PDX models. <sup>89</sup>Zr-DFO-IMAB362, <sup>89</sup>Zr-DFO-18.2-50H, and <sup>89</sup>Zr-DFO-18.2-50C were prepared with satisfactory radiochemical yield, specific activity, and stability. Tumors were clearly visible as early as 1 h post-injection of <sup>89</sup>Zr-DFO-18.2-50H, with an uptake value of 9.07 ± 2.36 %ID/g and a tumor-to-muscle ratio of 27.35 ± 3.72. Fc-fused <sup>89</sup>Zr-DFO-18.2-50C exhibited improved retention and higher tumor uptake than <sup>89</sup>Zr-DFO-18.2-50H and <sup>89</sup>Zr-DFO-IMAB362, with % ID/g increasing continuously from 5.07 ± 0.29 at 1 h to 32.95 ± 1.57 at 168 h. Notably, the introduction of the Fc chain also markedly increased the radiation exposure in the liver and spleen. Consistently, PET imaging in cynomolgus showed that <sup>89</sup>Zr-DFO-18.2-50C is mainly concentrated in the liver, but no apparent abnormality was observed. Furthermore, <sup>177</sup>Lu-DOTA-18.2-50C presented remarkable tumor selectivity with prolonged retention (16.92 ± 1.94 % ID/g at 5 d post-injection) in PDX models. Nanobody <sup>89</sup>Zr-DFO-18.2-50H demonstrated a superior tumor-to-background ratio, positioning it as a promising tracer for detecting CLDN18.2-overexpressing lesions. <sup>89</sup>Zr/<sup>177</sup>Lu-labeled VHH-Fc antibody 18.2−50C exhibited sustained higher tumor uptake than commercially available IMAB362 and provides a novel potential candidate for CLDN18.2-targeted radionuclide therapy.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5946–5955"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer 利用抗体-药物偶联物靶向治疗膀胱癌中的Nectin-4和TROP2
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-10-07 DOI: 10.1021/acs.molpharmaceut.6c00947
James L. Wood, Benedict Lum, Saikat Ghosh, Alexander H. Staudacher, Hari Shree Samyuktha Saravanan, Pie Huda, Alesia Ivashkevich, Peter Chandler, Michael Wheatcroft, Kristofer J. Thurecht
{"title":"Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer","authors":"James L. Wood,&nbsp;Benedict Lum,&nbsp;Saikat Ghosh,&nbsp;Alexander H. Staudacher,&nbsp;Hari Shree Samyuktha Saravanan,&nbsp;Pie Huda,&nbsp;Alesia Ivashkevich,&nbsp;Peter Chandler,&nbsp;Michael Wheatcroft,&nbsp;Kristofer J. Thurecht","doi":"10.1021/acs.molpharmaceut.6c00947","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00947","url":null,"abstract":"<p>The application of antibody-drug conjugate (ADC) therapies in advanced bladder cancers may be improved through non-invasive molecular imaging and therapy with targeted radiation. Enfortumab and Sacituzumab, the antibody components for the ADCs PADCEV (Nectin-4 targeting) and TRODELVY (TROP2 targeting), were developed as ImmunoPET and radioimmunotherapeutic modalities in a HT1376 xenograft model of advanced bladder cancer. Both immuno-PET agents displayed distinct tumor uptake in vivo, with Sacituzumab showing higher accumulation (% ID/g) compared to Enfortumab, reflecting the higher TROP2 expression in this tumor model over Nectin-4. Further, both [<sup>177</sup>Lu]Lu-DOTA-Enfortumab and [<sup>177</sup>Lu]Lu-DOTA-Sacituzumab were effective in reducing the growth of tumors in vivo. The repurposing of well-validated ADC antibodies as theranostic radiopharmaceuticals is a promising approach for alternative or adjuvant therapies.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5879–5890"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BBR-RHE Co-Loaded Nanoemulsion Potentiates Anti-PD-L1 Efficacy via Lipid Metabolic Reprogramming in Triple-Negative Breast Cancer BBR-RHE共载纳米乳通过脂质代谢重编程增强抗pd - l1的功效
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-10-07 DOI: 10.1021/acs.molpharmaceut.6c00398
Jiale Wei, Ke Qian, Jingbin Shi, Kexin Chen, Hongyan Zhang, Mancang Gu, Chaofeng Mu, Lifei Chen, Yang Xiong
{"title":"BBR-RHE Co-Loaded Nanoemulsion Potentiates Anti-PD-L1 Efficacy via Lipid Metabolic Reprogramming in Triple-Negative Breast Cancer","authors":"Jiale Wei,&nbsp;Ke Qian,&nbsp;Jingbin Shi,&nbsp;Kexin Chen,&nbsp;Hongyan Zhang,&nbsp;Mancang Gu,&nbsp;Chaofeng Mu,&nbsp;Lifei Chen,&nbsp;Yang Xiong","doi":"10.1021/acs.molpharmaceut.6c00398","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00398","url":null,"abstract":"<p>Triple-negative breast cancer (TNBC) therapy is limited by the poor efficacy of anti-programmed death-ligand 1 (aPD-L1) monotherapy, with dysregulated lipid metabolism in the tumor microenvironment (TME) driving immunosuppression. Herein, a nanoemulsion co-loaded with berberine (BBR) and rhein (RHE) (BBR-RHE-NE), two lipid-modulating bioactives from Dahuang Huanglian Xiexin Decoction, was fabricated to remodel the immunosuppressive TME and boost aPD-L1 efficacy in TNBC. BBR-RHE-NE was characterized with a small droplet size (185.8 ± 0.44 nm), narrow polydispersity (PDI: 0.12 ± 0.02), and good stability. In orthotopic 4T1<sup>Fluc</sup> TNBC mouse models, BBR-RHE-NE monotherapy inhibited tumor growth, and its combination with aPD-L1 exerted robust synergistic anti-tumor activity. Flow cytometry revealed that BBR-RHE-NE, as a monotherapy or in combination with aPD-L1, enhanced effector immune cell infiltration and reduced immunosuppressive subsets in both tumor tissues and spleens. Lipidomic analysis, Oil Red O staining, and enzymatic assays confirmed BBR-RHE-NE reduced intratumoral lipid droplet accumulation and downregulated intratumoral triacylglycerols and fatty acids (FAs) levels both in vitro and in vivo. Mechanistically, RNA sequencing and functional validation experiments demonstrated that BBR-RHE-NE potentiated aPD-L1 efficacy via PPARγ/FABP4-mediated lipid metabolic remodeling, a process that promoted dendritic cell maturation and was attenuated by the PPARγ agonist GW1929. Moreover, BBR-RHE-NE exhibited excellent biocompatibility with no detectable organ toxicity. Collectively, these findings demonstrate that BBR-RHE-NE effectively remodels the immunosuppressive TME through lipid metabolic reprogramming, offering a promising nanomedicine-based combinatorial strategy to enhance aPD-L1 immunotherapy for TNBC.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5367–5384"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proteomics Reveals Blood−Brain Barrier Membrane Protein Remodeling in Amyloid-β Pathology 蛋白质组学揭示了淀粉样蛋白-β病理中的血脑屏障蛋白重塑
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-09-26 DOI: 10.1021/acs.molpharmaceut.6c00935
Jooseppi Hyvärinen, Rositsa Todorovska, Maria del Pilar Palacios, Mikko Gynther, Alexey Afonin, Marko Lehtonen, Seppo Auriola, Liudmila Saveleva, Katja M. Kanninen, Gert Fricker, Elena Puris
{"title":"Proteomics Reveals Blood−Brain Barrier Membrane Protein Remodeling in Amyloid-β Pathology","authors":"Jooseppi Hyvärinen,&nbsp;Rositsa Todorovska,&nbsp;Maria del Pilar Palacios,&nbsp;Mikko Gynther,&nbsp;Alexey Afonin,&nbsp;Marko Lehtonen,&nbsp;Seppo Auriola,&nbsp;Liudmila Saveleva,&nbsp;Katja M. Kanninen,&nbsp;Gert Fricker,&nbsp;Elena Puris","doi":"10.1021/acs.molpharmaceut.6c00935","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00935","url":null,"abstract":"<p>The protective function of the blood−brain barrier (BBB) is achieved by membrane proteins expressed in the endothelial cells of brain microvessels, such as tight junction proteins, receptors, and transporters, which regulate the passage of solutes, including nutrients, drugs, and metabolites. In Alzheimer’s disease (AD), characterized by the accumulation of amyloid-β (Aβ) plaques, BBB dysfunction has been widely reported. However, quantitative information on Aβ-associated changes in the membrane proteome in the brain microvasculature remains limited. Here, we investigated the changes in abundances of membrane proteins playing roles in BBB function in the isolated brain microvessels of a mouse model mimicking human Aβ pathology, 5xFAD mice, versus corresponding wild-type (WT) mice using a state-of-the-art liquid chromatography tandem mass spectrometry (LC−MS/MS)-based data-independent acquisition (DIA) quantitative proteomics. In addition, we applied quantitative targeted absolute proteomics to evaluate the impact of Aβ<sub>1−42</sub> on the absolute protein abundance of multiple transporters in an <em>in vitro</em> model of brain endothelial cells, hCMEC/D3. We identified changes in the protein abundance of numerous proteins involved in BBB integrity, including tight junction-associated proteins and proteins implicated in Aβ transport and clearance, in the brain microvasculature of 5xFAD mice. Furthermore, Aβ<sub>1−42</sub> treatment altered GLUT1 protein abundance and the gene expression of <em>SLC27A1</em> and <em>SLC22A2</em> in hCMEC/D3 cells, which play roles in nutrient transport and drug disposition at the BBB. The present study provides novel insights into Aβ-associated molecular alterations in brain microvascular membrane proteins and advances our understanding of BBB changes in AD. The results may support the development of BBB-targeted therapeutic approaches and strategies for optimizing brain drug delivery in AD.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5848–5862"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combined siRNA Targeting IκBα and Stat6 Promotes Macrophage Reprogramming toward Cancer Immunotherapy 靶向IκBα和Stat6的siRNA联合促进巨噬细胞重编程用于癌症免疫治疗
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-09-27 DOI: 10.1021/acs.molpharmaceut.6c00510
Sezen Gul, Juliette Vergnaud, Qinglin Wang, Mélanie Hery, Florent Dumont, Pauline Tran, Séverine Domenichini, Claudine Deloménie, Mengyuan Cao, Jihana Achour, Jean-Luc Perfettini, François Fay, Elias Fattal
{"title":"Combined siRNA Targeting IκBα and Stat6 Promotes Macrophage Reprogramming toward Cancer Immunotherapy","authors":"Sezen Gul,&nbsp;Juliette Vergnaud,&nbsp;Qinglin Wang,&nbsp;Mélanie Hery,&nbsp;Florent Dumont,&nbsp;Pauline Tran,&nbsp;Séverine Domenichini,&nbsp;Claudine Deloménie,&nbsp;Mengyuan Cao,&nbsp;Jihana Achour,&nbsp;Jean-Luc Perfettini,&nbsp;François Fay,&nbsp;Elias Fattal","doi":"10.1021/acs.molpharmaceut.6c00510","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00510","url":null,"abstract":"<p>Tumor-associated macrophages (TAMs) are central regulators of the tumor microenvironment (TME). Their polarization state can critically influence tumor development and treatment resistance. In the TME, the pro-tumor M2-like phenotype is the most prevalent among TAMs and contributes to tumor progression by promoting immunosuppression, angiogenesis, and metastasis. Thus, reprogramming TAMs from an M2 to an antitumor M1-like phenotype is a promising strategy to enhance cancer immunotherapy by inhibiting these processes, stimulating inflammatory responses, and activating cytotoxic immune cells. In this study, an array of small interfering RNA (siRNA) targeting candidate genes to repolarize macrophages, <em>i</em>.<em>e</em>.<em>,</em> the inhibitor of nuclear factor kappa B alpha (IκBα), the colony-stimulating factor 1 receptor (Csf-1r), and the signal transducer and activator of transcription 6 (Stat6), was delivered by lipid nanoparticles (LNPs). While knockdown of all targeted genes was successful, silencing IκBα or Stat6 altered M1/M2 marker expression toward an M1-like polarization. Furthermore, combining IκBα and Stat6 produced the most effective macrophage reprogramming, achieving simultaneous downregulation of M2 markers and upregulation of M1 markers. Our data demonstrates that this dual-targeting strategy strongly induced potent reprogramming of M2-polarized macrophages, establishing it as a superior immunotherapeutic framework.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5426–5435"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149306085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reinforcement of Solid Lipid Nanoparticles for Targeted PD-L1 Downregulation in Breast Cancer 强化固体脂质纳米颗粒靶向PD-L1下调乳腺癌
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-10-05 Epub Date: 2026-09-08 DOI: 10.1021/acs.molpharmaceut.6c00750
Deniz Onan, Melike Özder, Gülşah Erel-Akbaba, Ece Çakıroğlu, Şerif Şentürk, Ayşe Gülten Kantarcı, Hasan Akbaba
{"title":"Reinforcement of Solid Lipid Nanoparticles for Targeted PD-L1 Downregulation in Breast Cancer","authors":"Deniz Onan,&nbsp;Melike Özder,&nbsp;Gülşah Erel-Akbaba,&nbsp;Ece Çakıroğlu,&nbsp;Şerif Şentürk,&nbsp;Ayşe Gülten Kantarcı,&nbsp;Hasan Akbaba","doi":"10.1021/acs.molpharmaceut.6c00750","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00750","url":null,"abstract":"<p>Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by the absence of targetable receptors and limited therapeutic options. Its inherently low immunogenicity necessitates strategies to enhance its susceptibility to immune attack. This study aimed to enhance the antitumor immune response by inducing downregulation of the programmed death ligand 1 (PD-L1), thereby increasing cancer cell recognition and activating tumor-specific immunity. To this end, a targeted solid lipid nanoparticle (tSLN) system was developed for the precise delivery of CRISPR/Cas9 plasmids to achieve functional PD-L1 downregulation. The SLN formulation comprised a cetyl palmitate core stabilized with cationic and PEGylated lipids. Functionalization with the tumor-penetrating peptide iRGD yielded tSLN, which demonstrated good colloidal stability, serum protection of the CRISPR cargo, and minimal cytotoxicity. In vitro studies in two breast cancer subtypes, the luminal MCF-7 and the triple-negative 4T1 line, confirmed greater transfection efficiency and PD-L1 knockdown by tSLN:Crispr/PD-L1 relative to non-targeted controls. In an orthotopic 4T1 mouse model, systemic administration of tSLN:Crispr/PD-L1 significantly inhibited tumor growth and metastasis while enhancing T cell infiltration, and was more effective than standard chemotherapy (paclitaxel) in this model. The targeted approach also exhibited a favorable short-term safety profile, with no organ toxicity detected over the treatment period. These findings underscore the potential of SLN-mediated CRISPR delivery as an immunomodulatory strategy for breast cancer, and particularly for TNBC.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 10","pages":"5069–5089"},"PeriodicalIF":4.9,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149093585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resiquimod Improves the Tumor Accumulation and Antitumor Activity of SN38 Prodrug-Loaded Liposomes 雷西喹莫特改善SN38前药负载脂质体的肿瘤蓄积和抗肿瘤活性
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-10-05 Epub Date: 2026-09-23 DOI: 10.1021/acs.molpharmaceut.6c00679
Tao Yang, Hongling Xu, Cheng Li, Manlin Wang, Xin Zeng, Yongjian Huang, Hongying Abamo, Qiong Man, Yaxin Zheng, Yang Li
{"title":"Resiquimod Improves the Tumor Accumulation and Antitumor Activity of SN38 Prodrug-Loaded Liposomes","authors":"Tao Yang,&nbsp;Hongling Xu,&nbsp;Cheng Li,&nbsp;Manlin Wang,&nbsp;Xin Zeng,&nbsp;Yongjian Huang,&nbsp;Hongying Abamo,&nbsp;Qiong Man,&nbsp;Yaxin Zheng,&nbsp;Yang Li","doi":"10.1021/acs.molpharmaceut.6c00679","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00679","url":null,"abstract":"<p>The effectiveness of liposome-based antitumor drugs is significantly limited by the poor tumor accumulation of liposomes. Herein, we report that resiquimod (R848) can selectively increase tumor accumulation of 7-Ethyl-10-hydroxycamptothecin (SN38)-loaded liposomes (SN38-LIPs) without significantly altering their pharmacokinetics. R848 enhanced the tumor distribution of SN38-LIPs and free SN38 by approximately 5-fold and 10-fold, respectively. This further resulted in greatly improved in vivo antitumor activity compared with those treated with R848 or SN38-LIPs alone (tumor inhibition rate: ∼95% versus ∼50%). The increased antitumor activity was associated with increased serum TNF-α and enhanced macrophage infiltration in the tumor. These results suggested that R848 held great potential to enhance the clinical antitumor effect of nanomedicine by increasing its tumor accumulation.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 10","pages":"5058–5068"},"PeriodicalIF":4.9,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149093651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书